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Abstract
Parenteral nutrition (PN) is a complex therapeutic modality provided to neonates, children, and adults for various indications.
Surveys have shown that current electronic health record (EHR) systems are in need of functionality enhancement for safe and
optimal delivery of PN. This is a consensus statement from theAmerican Society for Parenteral and Enteral Nutrition, theAcademy
of Nutrition and Dietetics, and the American Society of Health-System Pharmacists outlining some of the key challenges to
prescribing, order review/verification, compounding, and administration of PN using EHRs today and is a call to action for
clinicians and vendors to optimize their EHRs regarding the PN build and workflow. (Nutr Clin Pract. 2018;33:e1–e21)
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Parenteral nutrition (PN) is an important therapy pro-
vided to neonates, children, and adults. PN is a complex
medication containing up to 40 different ingredients.1 In
2013, PN was administered during approximately 302,000
hospital stays, while many other patients received this ther-
apy in the home or long-term care settings.2 The Institute
for Safe Medication Practices (ISMP) classifies PN as a
high-alert medication and recommends that strategies be
formulated to minimize harm and errors in patients receiv-
ing this medication.3 PN should only be used in patients
in whom the benefit outweighs the potential risks. In 2017,
the American Society for Parenteral and Enteral Nutrition
(ASPEN) published consensus recommendations on the
appropriate use of PN.4 A 2013 ASPEN survey with a gap
analysis revealed only 58% of healthcare organizations have
precautions in place to prevent errors and patient harm
associated with PN.5
The PN process most often involves a number of basic
steps, including prescribing, order review/verification, com-
pounding, labeling, and administration.6 PN ordering has
evolved over the years to include not only physicians as
prescribers, but also dietitians, nurse practitioners, phar-
macists, and physician assistants. The ASPEN Parenteral
Nutrition Safety Consensus Recommendations advised that
PN shall be prescribed using standardized electronic orders
via a computerized provider order entry (CPOE) system.6
In 2015, a work groupwas formed consisting of members
from ASPEN, the Academy of Nutrition and Dietetics
(Academy), and the American Society of Health-System
Pharmacists (ASHP). This work group consisted of experts
in PN, electronic health record (EHR) functionality, and
health information technology (HIT) standards. The work
group identified areas of opportunity for optimizing the
EHR in the PN workflow. The goals of the work group
were:
1. increase the awareness of EHR vendors to consen-
sus recommendations and guidelines for safe PN
ordering,6,7
2. recommend to EHR vendors opportunities to im-
prove PN process functionality and clinical decision
support (CDS),
3. encourage HIT standards for PN across the contin-
uum of care, and
4. publish a joint consensus statement on PN and EHR
best practices.
Key areas identified by the work group for this publica-
tion were:
1. standardized PN order and label;
2. CDS and warnings for macronutrient and micronu-
trient dosing, toxicity, and incompatibilities;
3. EHR interfaces, interoperability, and workflows in-
volving automated compounding devices (ACDs) –
functionality to improve safety and minimize risk of
errors;
4. ordering cyclic PN, taper up, and taper down; and
5. transition of PN from hospital to home or other
alternative care settings and vice versa.
The work group was divided into 5 subgroups, with
each assigned 1 of the above key areas of the consen-
sus statement. Each subgroup reviewed the literature and
developed evidence-based recommendations for their re-
spective area. Several members of the work group combined
the sections of the subgroups and developed the rough draft
of the paper. The paper was then revised based on review of
the entire paper by the entire work group. The leaders on the
work group from each organization identified appropriate
members within their organization to review and submit
comments on the final rough draft of the paper. The entire
work group discussed and came to consensus on revisions
of the paper based on reviewers’ comments to form the
final draft of the paper. The leaders on the work group
from each organization identified and sent the final draft of
the paper to the appropriate body within their organization
for final review, revision, and approval on behalf of their
organization.
Opportunities for Optimizing the EHR
in the PN Workflow
Standardized PN Order and Label
ASPEN recommends standardization as an error-
prevention strategy for creating lasting system changes
for the safe use of medications.8 A 2013 PN use survey
with a gap analysis reported 90% of organizations used
a self-defined standardized PN order form.5 This survey
also noted only 33% of those surveyed (298 of 895) used
a CPOE system for ordering PN. A follow-up survey
was performed in 2015,9 and 63% (436 of 689) of the
respondents replied they were using an electronic method
of ordering PN. Additionally, 78% (341 of 436) of the
respondents were using a self-defined standard electronic
method of PN ordering, with the others (95 respondents)
using a non-standard electronic method.
In 2007, ASPEN published a statement on PN stan-
dardization that advocated for a standardized process for
PN management to reduce variation and promote uni-
formity among healthcare organizations and clinicians.8
Recommended standard processes for PN in this statement
included: ordering, labeling, nutrition requirements, screen-
ing, administration, and monitoring.
The 2004 ASPEN Safe Practices for Parenteral Nu-
trition and the 2014 ASPEN PN Safety Consensus
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Recommendations supported the use of standardized order
formats for PN.6,10 The ASPEN PN Safety Consensus Rec-
ommendations also supported standardization throughout
the PN process.6 The PN process included: prescribing
and communicating the PN order, PN order review and
verification, PN compounding, and PN administration. The
Agency for Healthcare Research and Quality reported a
children’s hospital reduced PN errors from an average of
9 per 1000 PN orders in 2004 to approximately 2 per
1000 PN orders in 2011 by adopting a standardized PN
ordering and administration process.11 The ASPEN PN
Safety Consensus Recommendations stated that all PN
ingredients shall be ordered as amounts per day for adult
patients and amounts per kilogram per day in pediatric and
neonatal patients.6
PN prescribing and labeling, using an EHR, should
follow templates developed by the ASPEN PN Safety Task
Force as follows:1,12
 Standardized PN ordering templates for adults and
pediatric/neonatal patients (Figures 1 and 2, respec-
tively)
 Standardized PN labeling templates for adults and
pediatric/neonatal patients (Figures 3 and 4, respec-
tively)
 Standardized injectable lipid emulsions (ILE) la-
beling templates for adults and pediatric/neonatal
patients (Figures 5 and 6, respectively)
 Standardized Home or Alternate care setting PN
labeling templates (Figure 7 shows an example for
sadult patients)
The templates above should be adopted by clinicians and
EHR vendors to bring standardization to the prescribing
and labeling of PN.
CDS for Macronutrient and Micronutrient
Dosing, Toxicity, and Incompatibilities
PN is a highly complex medication with multiple indi-
vidual components including amino acids, dextrose, ILE,
electrolytes, minerals, vitamins, trace elements, insulin, and
other medications as well as solubilizers, emulsifiers, and
preservatives. Given the vast complexity, PN has the poten-
tial to cause significant patient harm, especially when errors
occur.13,14 The PN admixture needs to provide appropriate
amounts of macronutrients (amino acids, carbohydrates,
and lipids) and micronutrients (electrolytes, minerals, vita-
mins, and trace elements) for patients requiring PN based
on the patient’s clinical condition and laboratory status to
meet the maintenance needs and prevent malnutrition in
well-nourished patients and to treat deficiencies and restore
health in malnourished patients (Table 1). At the same time,
the PN admixture should not contain total amounts, con-
centrations, or rate of infusion of these nutrients that could
result in toxicities or make the admixture unstable resulting
in particulate matter which may include precipitates being
infused into the patient, either of which could cause signifi-
cant morbidity or mortality (Table 2). Recommended daily
and maximum doses of macronutrients and micronutrients
for neonatal and pediatric patients can be found in Table 3.
Furthermore, the ASPEN clinical guidelines provide some
specific metrics for use in CDS.7
There are 2 main types of PN admixtures: 2-in-1 (amino
acids and dextrose in 1 bag and ILEs given as separate
infusion in a different bag), and 3-in-1 (amino acids, dex-
trose, and ILEs infused together in same bag). When ILEs
were first introduced in the United States (U.S.) in the
mid-1950s, they were frequently associated with adverse
reactions, varying from minor fever to potentially life-
threatening anaphylaxis. As a result, ILEs were removed
from the market.20,34 When originally developed in the late
1960s, PN only included amino acids and dextrose (2-in-
1 admixture).34-36 Safer commercial ILEs using different
oils were subsequently available but were infused separately
from the amino acids and dextrose-based PNadmixture.23,37
By 1983, the U.S. Food andDrug Administration (FDA)
had approved 3-in-1 PN admixtures or total nutrient ad-
mixtures (TNA) in which all 3 macronutrients, i.e., amino
acids, dextrose, and ILEs, could be included in the same PN
bag.20,21 The TNA is an oil-in-water emulsion with tenuous
thermodynamic stability. Solubilizers improve water solu-
bility and emulsifiers can help prevent water soluble and fat
soluble components in the 3-in-1 PN from becoming unsta-
ble, causing the formation of coalesced fat particles greater
than 5 microns in diameter or separating out the water and
fat soluble components (“cracking” the emulsion), either of
which could cause severe complications, or even death, if
infused into a patient.
Despite the non-nutrient ingredients (emulsifiers and sol-
ubilizers), the final concentrations of many of the macronu-
trients and micronutrients in the 3-in-1 PN admixture
need to be kept within certain concentration thresholds
to prevent the admixture from destabilizing (Table 2). The
fat droplet surface in these emulsions have a net negative
charge, causing an electrostatic repulsion that keeps the
droplets from aggregating.37 Electrolyte cations are pos-
itively charged and have the potential to destabilize the
emulsion. Monovalent cations (potassium and sodium) are
less likely than divalent cations to destabilize the 3-in-1 PN
admixture, so they can be increased up to a total of 150
mEq/L combined concentration.20,21 The divalent cations
(calcium and magnesium) are much more likely to destabi-
lize the emulsion, so they need to be limited to 20 mEq/L
combined concentration.20,21 Anion electrolytes (acetate,
chloride, and phosphate) do not have specific concentration
limits for TNAs since they are negatively charged and have
little or no effect on emulsion stability.20
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Figure 1. Parenteral Nutrition Order Template: Adult Patient. CVC, central venous catheter; PN, parenteral nutrition.
Adapted with permission from Ayers P. ASPEN Parenteral Nutrition Safety Consensus Recommendations. JPEN J Parenter
Enteral Nutr. 2014;38(3):296-333.6
C© 2013 American Society for Parenteral and Enteral Nutrition
Calcium and phosphate are relatively insoluble and can
precipitate within a PN admixture. Infusion of these precip-
itates can cause significant morbidity and evenmortality.7,38
The solubility of calcium and phosphate is not only based
on the type and final concentrations of calcium and phos-
phate in the PN admixture but also varies based on the
final concentration and distribution of amino acids, final
concentration of dextrose, final concentration of magne-
sium, temperature at which PN is stored and administered,
the final pH of the PN admixture, other components
within the PN admixture, and the sequence in which the
components are added to the PN admixture.7,38 Keeping
the final concentrations of calcium and phosphate at or
below 8 mEq/L and 15 mmol/L, respectively, generally
should prevent calcium phosphate precipitation (Table 2).
However, this final concentration limit for phosphate is
relatively conservative and could be set higher, but the final
concentration limits for phosphate and calcium need to be
based on the calcium phosphate solubility curves specific
to the PN components being used. EHRs should have
the functionality of integrating the appropriate calcium
phosphate solubility curves into their CDS alerts.
EHRs should provide active real-time CDS alerts to
prescribers at the time of order entry to ensure adequate
provision of nutrients to avoid deficiencies and to prevent
administering too high of a daily dose, final concentra-
tion, or rate of infusion of nutrients that could result in
toxicity to the patient or instability of the PN admixture,
causing complications or even death. As a safety net,
the EHR should also provide CDS to pharmacists at the
time of PN order verification and compounding and to
nurses at the time of PN administration to avoid the
above adverse outcomes. Also, the PN admixture should
be included on the electronic medication administration
record (MAR).
EHR Interfaces, Interoperability, and
Workflows Involving ACDs – Functionality to
Improve Safety and Minimize Risk of Errors
ACDs should be fully integrated with EHR systems to
eliminate any manual transcription, including handwritten,
verbal, or fax transmission, in the PN workflow. There are
a variety of different types of interfaces. The interface for
PN orders should be a direct “automatic” interface that
does not require any manual action by a user to transmit
or download. Furthermore, PN orders should be retrieved
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Figure 2. Parenteral Nutrition Order Template: Pediatric/Neonatal Patient. CVC, central venous catheter; PN, parenteral
nutrition.
Adapted with permission from Ayers P. ASPEN Parenteral Nutrition Safety Consensus Recommendations. JPEN J Parenter
Enteral Nutr. 2014;38(3):296-333.6
C© 2013 American Society for Parenteral and Enteral Nutrition
in the ACD by scanning the PN label barcode (preferred
method), by using 2 patient identifiers (e.g., patient name
and date of birth), or by order ID number.
The ASPEN PN Safety Consensus Recommendations6
define “fully integrated” as the PN order entered into the
EHR system being transmitted electronically to the ACD
without requiring re-entry of any data, and any modifi-
cations to a PN order are electronically transmitted back
to the EHR system for prescriber approval and signature.
This avoids errors associated with manual transcription,
which has been reported as the most common cause for
errors in the PN process.39-41 The ASHP Guidelines for
the Safe Use of Automated Compounding Devices for
Preparation of PN Admixtures states that ACDs and ACD
software should alert when formulation issues are identified,
provide useful clinical information, integrate with existing
pharmacy programs, and meet the standards of ASPEN for
PN label formats.42
Sacks et al conducted a prospective, observational study
on the frequency of errors in the PN process at a large
university teaching hospital.39 PN errors were classified as
being related to prescribing, transcription, preparation, or
administration, and they categorized the severity of harm
associated with the errors. During an 18-month period,
an overall error rate of 1.6% was observed, and the most
common error was related to transcription (39%), which
included re-entry of PN orders into the ACD. Bonnabry
et al completed a systematic risk analysis on their pediatric
PN prescribing and preparation processes after implement-
ing several changes, including the elimination of manual
transcription.40 The greatest risk reduction identified was
in the elimination of transcription, followed by problems
reading the prescription. Both errors can be eliminated by
using standardized electronic orders and implementing fully
integrated systems that do not requiremanual transcription.
One retrospective cross-sectional study evaluating the im-
pact of an interactive computerized PN worksheet (outside
of the EHR system) on PN prescribing errors demonstrated
a reduction in prescribing error rate.41 However, separate
entry and transcription of the PN order was still required,
and the errors that occurred were due to transcription or
data entry mistakes.




Figure 3. Parenteral Nutrition Label Template: Adult Patient. CVC, central venous catheter; PN, parenteral nutrition.
*Specify product name
Adapted with permission from Ayers P. ASPEN Parenteral Nutrition Safety Consensus Recommendations. JPEN J Parenter
Enteral Nutr. 2014;38(3):296-333.6
C© 2013 American Society for Parenteral and Enteral Nutrition
A more recent study by MacKay et al in 2016 described
the frequency and severity of PN errors at a large aca-
demic pediatric hospital after implementing electronic PN
ordering and compounding, and this included eliminating
transcription.43 During a 7-year period, the frequency of
PN errors was 0.27%, compared with an error rate of 1.6%
reported by Sacks et al.39 In addition, 95% of errors were
associated with administration, and there were no errors
associated with transcription.43 These data suggest that
eliminating manual transcription can significantly reduce
errors associated with the PN use process. This also allows
the reviewing pharmacist to focus on evaluating the PN
order for both clinical and formulation considerations.
One area of concern is maintaining the security of
electronic systems and confidentiality of protected health
information (PHI). Hilmas and Peoples described their PN
process and pharmacist intervention rate.44 They did not
build an interface between their EHR and ACD, citing
concerns about the integrity of data in their EHR by
allowing access from an outside vendor. Outside vendors
of ACD software should adhere to the local facility policy
on patient matching and PHI security. Security of electronic
systems is a primary concern, and EHR and ACD vendors
should update and use the most secure methods for data
transmission and storage.
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Figure 4. Parenteral Nutrition Label Template: Pediatric/Neonatal Patient. CVC, central venous catheter; PN, parenteral
nutrition.
a Specify product name
b Since the admixture usually contains multiple sources of sodium, potassium, chloride, acetate, and phosphorus, the amount of
each electrolyte/kg provided by the PN admixture is determined by adding the amount of electrolyte provided by each salt.
Adapted with permission from Ayers P. ASPEN Parenteral Nutrition Safety Consensus Recommendations. JPEN J Parenter
Enteral Nutr. 2014;38(3):296-333.6
C© 2013 American Society for Parenteral and Enteral Nutrition
There should be a standardized additive sequence in ACDs
to optimize safety. The sequence of ingredients on PN
admixture should match between the EHR, the ACD, and
the PN label. The calculated total ingredients from ordered
units of measure should be listed in matching units on
the EHR, ACD, and PN label and should not require any
calculation, conversion, or manipulation. These templates
and calculations should be configurable for specific patient
populations.
Standardized PN order formats designed with ingredi-
ents listed in the same sequence may improve consistency
and potentially decrease the risk of errors, especially when
transitioning care.6,10 A children’s hospital adopted a stan-
dardized ordering and administration process for PN and
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Figure 5. Standard Injectable Lipid Emulsion Label Template: Adult. CVC, central venous catheter; PN, parenteral nutrition.
*Specify product name
Adapted with permission from Ayers P. ASPEN Parenteral Nutrition Safety Consensus Recommendations. JPEN J Parenter
Enteral Nutr. 2014;38(3):296-333.6
C© 2013 American Society for Parenteral and Enteral Nutrition
demonstrated a reduction in the average number of PN-
related errors in 2004 compared with 2011 (from 9 to 2 per
1000 PN orders).11
The ISMP has described several self-reported cases of
PN-related errors, some that were near misses (i.e., potential
for significant harm or death which fortunately did not
occur) and others that have resulted in death. One ISMP
report involved a premature infant weighing less than 1 kg
who died after receiving PN with 60 times more sodium
than prescribed.45 There were several points of failure in this
example:
 The prescriber ordered 14.7 mEq of sodium chloride
and 982 mg of calcium in the PN prescription.
 The pharmacy technician had to transcribe the pre-
scription into the ACD and inadvertently entered
the dose for calcium (982 mg) into the field for
sodium chloride (in mEq). This resulted in 982 mEq
of sodium chloride being compounded in the PN
admixture.
 The technician affixed the label from the ACD to the
PN admixture (with the incorrect sodium dose), but
the pharmacist failed to identify the error.
 A different label with the amounts from the original
prescription (listing 14.7 mEq of sodium chloride)
was placed over the label from theACD, and the error
was therefore unidentifiable by the nurse.
This series of tragic errors, i.e., prescribing, transcription,
labeling, and dispensing errors, highlights the need to fully
integrate EHR systems with ACDs, avoid manual transcrip-
tion of PN orders, optimize and utilize CDS, and match PN
prescribing templates with PN templates in ACDs and on
PN labels.
Another case reported to ISMP was a 16-year-old boy
who received a PN admixture in which the ingredients
were ordered in amounts per kg, but the PN order was
manually transcribed to amounts per day.46 This resulted
in an infusion of a hypo-osmolar PN admixture (138
mOsm/L) with very low doses of nutrients (i.e., amounts
in g/day rather than g/kg/day) for almost an entire day
before it was identified. Fortunately, no adverse effects
were incurred by the patient. There were multiple failures
across the entire medication use process in this scenario.
For example, the PN order template in the EHR system
did not match the template in the pharmacy system and the
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Figure 6. Standard Injectable Lipid Emulsion Label Template: Neonate or Pediatric Patient. CVC, central venous catheter; PN,
parenteral nutrition.
* Specify product name
Adapted with permission from Ayers P. ASPEN Parenteral Nutrition Safety Consensus Recommendations. JPEN J Parenter
Enteral Nutr. 2014;38(3):296-333.6
C© 2013 American Society for Parenteral and Enteral Nutrition
ACD.Furthermore, therewas a lack of CDS and automated
warnings in both the EHRPNorder template and the ACD,
a lack of redundancies in the process, andmultiple points of
transcription.
ISMP has provided several safe practice recommen-
dations, in part based upon these and other reported
errors:45,46
 Match prescribing and pharmacy templates
 Build, test, and heed automated warnings
 Heighten suspicions of errors
 Integrate effective redundancies
 Provide clear labeling that matches the sequence of
ingredients in the PN order templates in the EHRPN
order form or CPOE system and the ACD
 Educate and validate competency of all clinicians
involved in the PN process
 Eliminate manual transcription of PN orders
Total calculated ingredients in the PN bag should be
displayed and available for viewing on the EHR and ACD
to support prepared admixture checking between multiple
systems. Calculations between the systems, furthermore,
should allow for rounding to a specified decimal place
supported by the EHR and ACD.
EHR systems, ACDs, and their interfaces should be si-
multaneously modifiable, with appropriate review and veri-
fication from the pharmacist, to change individual product
ingredients to reflect availability, shortages, conservation, etc.
and to prevent ordering unavailable products. Medication
shortages have significantly impacted patients, healthcare
professionals, and health systems during the past several
years. The U.S. FDA reported 251 shortages (183 injecta-
bles) in 2011, compared with approximately 61 shortages in
2005.47 They have worked with stakeholders to implement
measures to avoid or prevent medication shortages, as well
as improve communication from manufacturers regarding
shortages. FDA’s First Annual Report on Drug Shortages
for Calendar Year 2013 noted that medication shortages
continue to pose a challenge to public health, particularly
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Macronutrients Amount/day
Figure 7. Standard Home PN Label Template: Adult Patient (as an example). CVC, central venous catheter; PN, parenteral
nutrition.
a Specify product name
Adapted with permission from Ayers P. ASPEN Parenteral Nutrition Safety Consensus Recommendations. JPEN J Parenter
Enteral Nutr. 2014;38(3):296-333.6
C© 2013 American Society for Parenteral and Enteral Nutrition
when they involve a “critical drug,” such as those used to
provide PN to patients.47 These efforts have contributed to a
significant reduction in shortages, with the 2015 FDA report
showing only 26 total, including 15 injectable medication
shortages as well as prevention of a significant number of
shortages (142 of which 92 were injectables).48 There have
been several very serious and tragic outcomes, including
patient deaths, as a result of PN-related shortages, including
contamination of compounded amino acid products during
an amino acid shortage,49 selenium deficiency in pediatric
patients with intestinal failure,50 and anemia and leukopenia
in patients receiving long-term PN.51 Mainstream media
have also highlighted the devastating effects of PN-related
shortages on patients, especially in children (e.g., “Children
are Dying” article in The Washingtonian in 2013).52 Of the
683 respondents to an ASPEN survey, PN-related medica-
tion shortages interfered with the ability to meet patient
micronutrient (70% of respondents) or macronutrient (47%
respondents) needs, and directly affected patient outcome
(16% respondents).5
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Table 1. General Recommendations for Adult Daily Doses of Macronutrients and Micronutrients in a Parenteral Nutrition
Admixture.a
1. Amino Acids –√
0.8–2.5 g/kg/day (varies depending if patient normally nourished and using for maintenance therapy, malnourished
and using for repletion therapy, or critically ill and using for metabolic support)1,15√
Approximately 20% of total energy (kcal/d)16
2. Dextrose – approximately 50% of total energy (kcal/d) and about 60%–70% of non-protein energy (kcals/day)16
3. Fatty Acids –√
Provide at least 2%–4% of total energy intake as linoleic acid and 0.25%–0.5% as alpha linolenic acid to prevent
essential fatty acid deficiency17√
Can provide fatty acids as 30% of total energy (kcal/day) and about 30%–40% of non-protein energy/day as alternative
non-protein energy source to dextrose15,16
4. Total Energy Requirements – 20–30 kcal/kg/day (depending if used for maintenance, repletion, or metabolic support
therapy)1,16
5. Fluid Requirements – 30–40 mL/kg/day (varies based on patient’s fluid status, fluid needs, and co-morbidities)1
6. Minerals –√
Calcium – 10–15 mEq/day1√
Magnesium – 8–20 mEq/day1√
Phosphorus – 20–40 mmol/day1
7. Electrolytes –√
Sodium – 1–2 mEq/kg/day1√
Potassium – 1–2 mEq/kg/day1√
Acetate – as needed to maintain normal acid–base balance1√
Chloride – as needed to maintain normal acid–base balance1
8. Vitamins – should include daily doses13,15 and are usually provided by parenteral multivitamin products, although some
vitamins are available as individual parenteral products. Recommended daily parenteral doses:18√
Fat-Soluble Vitamins
 Vitamin A – 990 mcg or 3300 IU
 Vitamin D – 5 mcg or 200 IU (some patients may need higher doses)
 Vitamin E – 10 mg or 10 IU
 Vitamin K – 150 mcg√
Water-Soluble Vitamins
 Vitamin B1 (thiamin) – 6 mg
 Vitamin B2 (riboflavin) – 3.6 mg
 Vitamin B3 (niacin) – 40 mg
 Vitamin B5 (pantothenic acid) – 15 mg
 Vitamin B6 (pyridoxine) – 6 mg
 Vitamin B12 (cyanocobalamin) – 5 mcg
 Vitamin C (ascorbic acid) – 200 mg
 Folate – 600 mcg
 Biotin – 60 mcg
9. Trace Elements (TE) – should include daily doses15,16 and usually provided by parenteral multi-TE products, although
many TE are available as individual parenteral TE products. Recommended daily parenteral doses are currently in flux
(see ASPEN position papers18,19).
aThese recommendations are not intended to supersede the judgment of the healthcare professional based on the circumstances of the individual
patient.
ISMP conducted a survey of more than 1800 healthcare
professionals (68% of which were pharmacists) in 2010.53
This survey focused on medication shortages and was
disseminated near the peak in medication shortages in 2011.
While the survey was not specific to PN-related shortages,
the results were nevertheless alarming. Approximately 35%
of respondents reported a near miss (over 1000 near misses
reported), approximately 25% reported an error, and about
20% reported an adverse patient outcome. Many of these
included medications that were high alert or considered
essential and life-saving with no suitable alternatives,
including PN-related products such as intravenous (IV)
electrolytes and ILEs. There was also significant frustration
regarding shortages, including little or no information
about the duration of a shortage (85%), the lack of
advanced warning of a shortage (84%), and substantial
resources spent investigating and developing a plan
of action.53
ISMP conducted another survey on PN-related short-
ages in 2014 and included 234 healthcare profession-
als (81% of which were pharmacists).54 Up to 28% of
respondents reported a medication error related to the
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Table 2. Adult Limits for Daily Dose, Final Concentration, or Infusion Rates for Macronutrients and Micronutrients for 2-in-1
(Dextrose and Amino Acids Only) and 3-in-1 (Dextrose, Amino Acids, and Lipid Emulsion Altogether) Parenteral Nutrition
Admixtures to Prevent Toxicities or Solubility Incompatibilities.a
1. Amino Acids –√
Final Concentration Limits –
 2-in-1 PN – no specific limits
 3-in-1 PN – should be greater than or equal to 4% to avoid destabilizing the admixture7,20,21√
Daily Dose – no specific limits√
Infusion Rates – no specific limits
2. Dextrose –√
Final Concentration Limits –
 2-in-1 PN – no specific limits
 3-in-1 PN – should be greater than or equal to 10% to avoid destabilizing the emulsion7,20,21√
Daily Dose – no specific limits√
Infusion Rates – generally less than or equal to 4 mg/kg/min for critically ill patients and less than or equal to 7
mg/kg/min in stable patients,1 but infusion rates need to be based on patient’s individual needs and co-morbidities√
Maintain blood glucose levels less than or equal to 180 mg/dL1
3. Fatty Acids –√
Final Concentration Limits –
 2-in-1 PN – not applicable (infused separately from PN admixtures with available products of 10% or 20% ILEs)17
 3-in-1 PN – should be greater than or equal to 2% to avoid destabilizing the emulsion7,20,21√
Daily Dose –
 should not exceed 60% of total energy or 2.5 g/kg/day17√
Infusion Rates – should be administered at a rate less than or equal to 0.11 g/kg/hr to avoid overload of the
reticuloendothelial system, which can cause pulmonary, hepatic, and platelet dysfunction;10,21-23 to minimize the risk of
infection, individual ILE containers should not hang any longer than 12 hours, while ILE within 3-in-1 PN can hang
up to 24 hours a day.10,21√
Maintain serum triglyceride levels less than or equal to 400 mg/dL1
4. Mineral√
Calciumb – final concentration of calcium is limited by calcium/phosphorus stability curve, but a safe limit is 8 mEq/L;
to avoid instability for 3-in-1 PN admixtures, the final concentration of the combination of magnesium and calcium
should not exceed 20 mEq/L.20,21√
Phosphorusb – a safe final concentration is 15 mmol/L, but higher limits could be administered based on the
calcium/phosphorus solubility curves for the PN components being used.20,24√
Magnesium – final concentration of the combination of magnesium and calcium should not exceed 20 mEq/L to avoid
instability in 3-in-1 PN admixtures.20,21
5. Electrolytesa√
Potassium –
 Final Concentration – should not exceed 100 mEq/L25,26
 Rate:
◦ Not on cardiac monitor – should not exceed 10 mEq/hr26
◦ On cardiac monitor – should not exceed 20 mEq/hr26√
Sodium – final concentrations of potassium and sodium combined should not exceed 150 mEq/L to avoid instability
of 3-in-1 PN admixtures;20,21 while there are no specific limits for 2-in-1 admixtures, exceeding 154 mEq/L of sodium
will result in a hypertonic admixture and should be avoided.√
Acetate – no specific limit√
Chloride – no specific limit
6. Vitamins and Trace Elements – see Table 1
7. Osmolarity – no specific limits if administered via central venous catheter but should be less than or equal to 900 mOsm/L
if administered via peripheral vein7,15,26,27
aThese recommendations are not intended to supersede the judgment of the healthcare professional based on the circumstances of the individual
patient.
bFinal concentrations of minerals and electrolytes for stability regarding calcium phosphorus precipitation and stability of 3-in-1 admixtures vary
depending on the amino acid solution and other PN components used, so all manufacturer’s recommendations regarding limits on final
concentrations of mineral and electrolyte concentrations in PN admixtures should be checked.
PN, parenteral nutrition; ILEs, injectable lipid emulsions.
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Table 3. Recommended Neonatal and Pediatric Daily and Maximum Doses of Macronutrients and Micronutrients in Parenteral
Nutrition Admixtures.a
1. Amino Acids28,29√
Protein intake should be between 10%–20% of the total energy in children√
Premature infant – 1–3 g/kg/day (maximum 3–4 g/kg/day)√
Younger than 1 year of age – 1–2 g/kg/day (maximum 3 g/kg/day)√
1–10 years of age – 1–2 g/kg/day (maximum 1.5–3 g/kg/day)√
Older than 10 years of age (adolescents) – 1 g/kg/day (maximum 2.5 g/kg/day)
2. Total Energy Requirements28√
Premature infant – 120–150 kcal/kg/day√
Younger than 6 months of age – 90–129 kcal/kg/day√
6–12 months of age – 80–100 kcal/kg/day√
1–7 years of age – 75–90 kcal/kg/day√
7–12 years of age – 60–75 kcal/kg/day√
12–18 years of age – 30–60 kcal/kg/day
3. Dextrose28,29√
Carbohydrate intake should be between 50%–60% of the total energy for children
Dextrose Requirements
Age Group Dextrose
Younger than 1 year Initial: 6–8 mg/kg/min
Goal: 10–14 mg/kg/min
Maximum: 14–18 mg/kg/min
1–10 years Initial: 3–6 mg/kg/min
Maximum: 8–10 mg/kg/min
Older than 10 years Initial: 2.5–3 mg/kg/min
Maximum: 5–6 mg/kg/min
4. Fatty Acids28,30√
Fat intake should provide between 20%–30% of the total energy (may be higher with peripheral PN)√
Maximum infusion rate should not exceed 0.15 g/kg/hr√
Minimum dose needed to prevent the development of an essential fatty acid deficiency (EFAD) depends on the
fatty acid source of the lipid being used. In the older patient providing at least 2%–4% of the energy requirements
from linoleic acid and 0.25%–0.5% of the energy requirements from alpha linoleic is needed to prevent the
development of EFAD. Preterm infants should receive a minimum of 0.25 g/kg lineoleic acid, whereas the term and
older infants should receive at least 0.1 g/kg linoleic acid.
Fat Requirements
Age Group Lipids
Younger than 1 year Initial: 1–2 g/kg
Maximum: 3 g/kg
1–10 years Initial: 1–2 g/kg
Maximum: 2–25 g/kg
Older than 10 years Initial: 1 g/kg
Maximum: 1–2 g/kg
Continue
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Table 3. Continued.
5. Fluid Requirements31
Daily Fluid Maintenance Requirement for Pediatrics
Body Weight Amount of Fluid per Day
Less than or equal to 10 kg 100 mL/kg
Greater than 10 kg and less than or equal to 20 kg 1000 mL + 50 mL/kg over 10 kg
Greater than 20 kg 1500 mL + 20 mL/kg over 20 kg
6. Minerals28,32
Neonates 1 month–1 year 1–3 years 4–10 years
Older than 10
years
Calcium, mEq/kg/day 2–3 0.6–1 0.5 0.5 0.25–0.5
Magnesium,
mEq/kg/day
0.25–0.5 0.5 0.5 0.5 0.25–0.5
Phosphorus,
mmol/kg/day
1–2 1 0.8 0.6 0.25–0.5
7. Electrolytes28
Neonates 1 month–1 year 1–3 years 4–10 years
Older than 10
years
Sodium, mEq/kg/day 2–5 3–4 3–4 2–3 1–2
Potassium,
mEq/kg/day
2–3 2–3 2–3 2–3 1–3
8. Vitamins – should include daily doses and are usually provided by parenteral multivitamin products, although some
vitamins are available as individual parenteral products. Doses of individual vitamins dependent on age and
weight.18,29,32,33
9. Trace Elements (TE) – should include daily doses and usually provided by parenteral multi-TE products, although many
TE available as individual parenteral TE products. Doses of individual vitamins dependent on age and weight.19,32
aThese recommendations are not intended to supersede the judgment of the healthcare professional based on the circumstances of the individual
patient.
PN, parenteral nutrition.
inability to obtain 1 of the products used in PN, most
commonly involving calcium gluconate, ILEs, multivita-
mins, sodium and potassium phosphate, and trace elements.
One of every 4–5 respondents reported preventable ad-
verse outcomes due to PN-related shortages. The com-
mon contributing factors to PN shortage-related errors
included:54
 not making changes to protocols, templates, work
labels, compounders, or order entry systems,
 mix-ups between electrolyte salts,
 confusion between pediatric and adult alternative
products, and
 differences in concentration with alternative prod-
ucts.
Most, if not all, of these contributing factors (and
potentially the associated errors) could be avoided with en-
hanced functionality of CDS within and interfaces between
EHRs, ACDs, and pharmacy systems. Enhancements in
the EHR could also improve communication to healthcare
professionals regarding PN-related medication shortages.
While PN-related medication shortages require a compre-
hensive management plan, a critical part of the plan must
include enhanced functionality and optimization of EHRs,
ACDs, and pharmacy systems.55,56 Potential advantages
and functionality can include:
 reporting (e.g., prescribing and use data to guide the
plan and target changes and/or education);
 blocking products that are not available;
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 directing prescribers to appropriate alternative prod-
ucts;
 using CDS (ideally at the time of order entry) to con-
duct automatic calculations of PN components in the
background when using different products that have
different components and/or different concentration
of components;
 using CDS to calculate total amounts of ordered
electrolytes from multiple components within the
PN; and
 educating and communicating with healthcare pro-
fessionals regarding PN component and alternative
product availability.
The ACD–EHR interface should transmit amounts of
the calculated total ingredients, especially if electrolytes
are ordered by their ions instead of by salts. ASPEN
guidelines recommend salt-based ordering of electrolytes
due to limitations of existing systems and EHRs to safely
and appropriately calculate the final total ingredients in the
PN admixture.6 Ion ordering is acceptable if the EHR can
calculate and display the amounts of each electrolyte salt
used to compound the PNadmixture at the time of order en-
try, pharmacist verification, and on the label. Also, the EHR
should be able to calculate and display the total amounts of
electrolyte in the PN admixture, including electrolytes from
the amino acid solutions as well as the ordered amounts
of additional electrolytes. This is especially important when
different amino acid solutions must be substituted during
times of shortages.
Barcode scanning technology should be used when hanging
and exchanging products used on ACDs and in compounding
PN admixtures. EHR vendors should collaborate with ACD
vendors and develop systems using a standardized format that
will allow a direct electronic interface between any EHR and
ACD systems. The Health Level Seven (HL7) version 2x
clinical messaging standards are used for transmitting data
from the EHR to ancillary systems. Current HL7 version
2x standards (versioning changes with updates) have the
ability to transmit patient information, insurance, diagnosis,
allergies, orders for all clinical departments, results for
tests ordered, and any updates of these data.57 Interfaces
frequently are designed to take advantage of HL7 standards
to improve the speed and accuracy with which systems
can be integrated.58 Discussion with the HL7 Pharmacy
Working Group concerning PN-specific content in evolving
HL7 standards included the following suggestions:59
 complete a use case and an activity diagram which
shows possible mechanism of the PN order,
 share ASPEN PN Safety Consensus Recommenda-
tions6 with HL7 Pharmacy Work Group,
 recommend additional work on PN orders within
HL7 Standards, and
 share ASPEN PN Safety Consensus
Recommendations6 with theHealthcare Information
Management and Systems Society (HIMSS) EHR
Association, the Office of the National Coordinator
of Health IT, and other relevant EHR groups or
alliances.
EHR–ACD interfaces should allow “versioning” to sup-
port PN order modification workflows (i.e., 1 order sent,
then modified, most recent order should reflect changes).
Currently HL7 allows for order versioning within common
order segments via placer order numbers and order control
field values.57 A message from the ACD to the EHR to
indicate whether a bag has already been prepared for that
day can allow for CDS to verify order modification and
reduce provider calls or waste for less significant modifi-
cations. The ACD should have alerts noting the existence
of a new version of a PN order to prevent queuing an
outdated admixture for compounding or to prompt the
user to locate and replace an already compounded bag.
ACD vendors should also develop screens similar to those
currently found in clinical nutrition management software.
These ACD software screens should show all PN orders
and changes placed for a patient during that admission in
chronologic order and with placer order numbers.
Any modifications made to the PN order should be sent back
to the provider for review and electronic signature. At min-
imum, EHR settings should be coded to require provider
review when the order is placed. All PN order changes
should be reviewed by a pharmacist. PN orders should
be entered by a prescriber and reviewed and verified by a
pharmacist within the EHR prior to order transmission to
an ACD with a permanent record of the individual’s name
and the date and time of the order and order verification.
CDS should be used in both the EHR and the ACD.6
Ideally, CDS and evaluation of the PN order should first
be completed within the EHR at the time of order entry
and again at the time of order review and verification. If
CDS is not available within the EHR, then CDS should
be available and optimized within the ACD. The EHR and
ACD should allow for setting soft-stop and hard-stop CDS
alerts, limit alerts, and “best practice” alerts, and these
should be configurable and customizable by the healthcare
system pharmacy build team.6 CDS used in the EHR and
ACD should be configurable to be complementary and
compatible to reduce duplicative alerts and unnecessary
rework. CDS used in the EHR and ACD should also be
redundant when possible, in order to detect and prevent
errors in interfacing and better support downtime. When
it is not possible for CDS to reconcile the EHR and ACD
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alerts, the option for the incompatible CDS alerts to be
disabled should be available.
Published data have demonstrated that using electronic
systems and CDS can reduce the likelihood of errors.
One systematic review suggested that most studies on HIT
report positive effects on safety, quality, and efficiency.60
In addition, about 78% of studies on HIT reported some
positive effects on safety for a wide range of medications in
a variety of healthcare settings. CDS, including automatic
dose-calculation features, resulted in a relative reduction in
medication dosing errors by 37%–80%.60
CDS tools should be flexible enough to accommodate
practice and resource differences between institutions. This
flexibility should provide the correct CDS to the right user
in the ordering workflow supported at the institution. Any
unique warnings or alerts that may suggest a need to modify
an order should be displayed at the time of ordering and
decision making to prescribers authorized to order PN
therapy.
The CDS should allow customization of soft-stop and
hard-stop limits for component ingredients. Furthermore,
CDS should include several features, including (but not
limited to):
 dosing alerts (both upper and lower limits for clinical
effectiveness and stability of the PN admixture)
available in all possible units of measurement (e.g.,
amounts per day, amounts per dose, amounts per
kg per day, amounts per kg per dose, amounts per
volume [L], concentration [%], etc.), taking into ac-
count whether the PN is being administered through
a central or peripheral line;
 auto-populating fields (automatically pulling in in-
formation available in the system avoiding manual
entry of this information);
 requiring mandatory fields to be completed before
order entry;
 using checkboxes or drop-down menus instead of
free text when possible; and
 using precipitation warnings for calcium and phos-
phorus based on the appropriate calcium-phosphate
solubility curves for PN components ordered.
Unfortunately, adoption of EHRs and CDS to improve
safety of the PN process has been limited. In recent
surveys, only 33%–63% of respondents reported using an
electronic order for PN and only 50%–54% utilized dosing
guidelines and CDS built into the system.5,9 Furthermore,
only about 28% of respondents reported that they had an
automatic interface between the EHR and ACD at their
institution.9
While the use of CDS can improve safety, alert fatigue
(end users ignoring alerts after frequently being presented
with clinically insignificant alerts) is a serious concern. Alert
fatigue can be a potential barrier to successful adoption
and optimization of CDS and can lead to undesirable
outcomes.60 In 1 review of 17 studies, drug safety CDS alerts
were overridden in 49%–96% of cases, and adverse events
occurred in 2.3%–6% of overridden alert cases in the 3 stud-
ies that reported this additional data.61 Overriding an alert
can be appropriate in some situations, but CDS alerts must
be designed with high sensitivity and specificity to minimize
alert fatigue and the need for overrides.61 Many factors
can contribute to alert fatigue, starting with the design of
the CDS alerts, all the way through implementation and
end-user interpretation. CDS must be designed to minimize
“false positives,” “false negatives,” and unclear alerts, all
of which can lead to disruptions in workflow, alert fatigue,
distrust of the system, excessive overrides, and unnecessary
added workload, and ultimately result in adverse patient
effects.61 Also, for maximal efficiency, whenever possible,
CDS alerts should be configured so the alert is actionable,
i.e., the end user can make appropriate changes to the
order within the alert, avoiding multiple clicks to make the
changes.
Tools should exist in the EHR and ACD to capture failed
message transfers and support downtime of the automatic
interface. An error message with a description of the error
(ingredient mismatch, failed transmission, etc.) should dis-
play to relevant end users to communicate failed interface
messages so that the error may be addressed. The option to
resubmit a message to the ACD should also exist so that the
message may be retransmitted following issue resolution. In
the event of a longer downtime, the ability to produce a
message and manually transfer this to the ACD should also
exist.
EHRs should accommodate outsourcing of PN compounding
without requiring manual transcription of the PN orders.
Some hospitals outsource the compounding of PN to an
offsite, independent compounding pharmacy. Most of the
time, the outsourced pharmacy is on a different electronic
system than the hospital and may not even have access
to the EHR used within the hospital, making it even
more challenging to create a direct interface between the
provider PN order entry and the ACD. This is similar to the
concerns raised in issue number 5 below when transitioning
PN patients from hospital to home or vice versa. These
scenarios raise the issue of interoperability between different
EHR systems and the importance of being able to transfer
healthcare information, including complex orders, such
as PN, safely, efficiently, and accurately between different
healthcare organizations while minimizing the need for
duplicative manual entry of ordering parameters.
Ordering Cyclic PN, Taper Up, and Taper Down
Most hospitalized patients receiving PN therapy receive
continuous PN, but some patients require cyclic PN. Cyclic
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PN involves infusion of the PN over a certain number of
hours per a 24-hour period of time and off PN the rest
of that period of time. Cyclic PN may be used when a
patient is being transitioned from PN to enteral or oral
nutrition, preparation for transition to home PN, or if
continuing cyclic PN that the patient was receiving prior
to hospitalizations.6,62 A 2010 review of the literature62 on
the metabolic effects of cyclic PN infusion in adults and
children revealed no significant differences in nitrogen bal-
ance or circulating counter regulatory hormones comparing
patients on cyclic vs continuous PN infusion. Cyclic PN
infusion may stabilize or improve elevated liver enzyme tests
in patients who previously were receiving continuous PN
infusion.62 Cyclic PN infusion was not associated with any
significant increase in calcium, phosphorus, magnesium, or
vitamin D losses.62 The ability to order cyclic PN should
be included in the ordering functionality of all inpatient
EHRs. Order parameters for cyclic PN should include the
total volume of PN to infuse and the time period during
which to infuse it, which can range from 8 hours to 20 hours
with 12 hours being the most common infusion time period.
Cyclic PN can be ordered to abruptly start at the full rate
at the beginning of the infusion and abruptly stop at the
end of the infusion. Alternatively, the rate can be ordered
to gradually taper up at the beginning of the infusion (taper
up) and/or gradually taper down at the end of the infusion
(taper down). Some PN infusion pumps, mostly ambulatory
PN pumps, can automatically taper up and/or taper down
the PN rate of infusion during the specified time period,
usually 1–2 hours each, as well as calculate the rate to infuse
the PN between the taper up and taper down periods in
order to infuse the entire amount of PN ordered. If the
PN infusion pump does not have this functionality, then the
ordering provider will need to specify the taper up and taper
down parameters as well as the rate throughout the middle
of the infusion, and the caregiver will need to manually
change the infusion rate at the specified periods of time to
the specified infusion rates.
One study63 of 14 adult PN patients monitored blood
samples every 5 minutes for 2 hours at the start of PN
infusion without any taper up. The blood glucose level (BG)
increased a mean of 60 mg/dL over the mean baseline of
127 + 76 mg/dL. Patients with diabetes had a higher mean
increase in BG compared with patients without diabetes (79
+ 14mg/dL vs 52+ 23mg/dL), but there was no correlation
between the amount of rise in BG and either the baseline
BG or the amount of glucose infused. The majority of
the rise in BG occurred in the first 60 minutes, and there
were no incidences of clinically significant hyperglycemia
without the use of a taper up. However, in another study64
of 38 adult hospitalized PN patients being transitioned
from continuous to cyclic PN in preparation for discharge
to receive home PN, 18% of the patients developed severe
hyperglycemia, i.e., BG greater than 250 mg/dL, and in
all of these patients, the severe hyperglycemia occurred
when they were being switched from 16 hours a day to 12
hours a day. The authors recommended close monitoring
of BG when transitioning from continuous to cyclic PN,
especially in patients with end-stage liver failure, acute or
chronic renal failure, insulin-dependent diabetes mellitus, or
decompensated congestive heart failure.
A total of 86 adult patients from 4 studies63,65-67 who
had their PN stopped abruptly with no taper down,
showed transient decreases in BG, mainly within the first
hour after stopping the PN, with no patients experiencing
symptomatic hypoglycemia. One randomized, controlled
trial crossover study65 of 12 patients receiving cyclic PN,
comparing taper down and no taper down, showed no
significant differences between taper and no taper in the
mean BG, insulin, epinephrine, norepinephrine, glucagon,
growth hormone, or cortisol levels when checked before
taper or abrupt discontinuation and every 15 minutes for
1.5 hours after discontinuation of PN.
Two studies68,69 have studied taper down in pediatric
patients. One study68 included 14 pediatric PN patients
ranging in age from 2.5–14 years, with a mean age of 8.0 ±
3.5 years. After abrupt discontinuation of PN, the mean BG
level decreased from 117 mg/dL to 83 mg/dL at 15 minutes
after discontinuation, with no further significant change at
30 minutes after discontinuation. Mean serum insulin levels
were elevated prior to PN discontinuation and significantly
dropped at 15 minutes after discontinuation, with only a
small further decrease at 30 minutes after discontinuation.
Only 1 patient developed hypoglycemia, i.e., BG less than
60 md/dL, but this patient was on high-dose steroids and
had a high glucose-to-insulin ratio prior to discontinuation
of PN. No patients developed symptoms of hypoglycemia.
The authors concluded that abrupt discontinuation of PN
is safe in “most” children older than 2 years.
The second study69 involved 11 younger pediatric PN
patients (mean age 12.3 months, range 1.5–36 months).
After abrupt discontinuation of PN, 6 (55%) of these
patients developed hypoglycemia, defined as BG less than
40mg/dL, with stabilization of BG in these patients ranging
from 15–45 minutes. Ten of the patients were studied again
with a 1-hour taper down before PN discontinuation, and
2 (20%) of these patients developed hypoglycemia. One
of these patients also had developed hypoglycemia after
abrupt discontinuation of PN, while the other did not. Of
the 8 hypoglycemic episodes, in only 2 instances was there
any clinical sign of hypoglycemia, which was manifested
by sleepiness, and in only 1 instance was the hypoglycemia
treated. Hypoglycemic episodes did not correlate with pa-
tient’s age or glucose infusion rate. The authors concluded
that due to a high incidence of hypoglycemia after abrupt
discontinuation of PN in children less than 3 years, BG
of these patients needs to be closely monitored at the time
of PN discontinuation. Also, a 1-hour taper down did not
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completely avoid hypoglycemia, so a longer taper down
period may be more beneficial.
The 2014 ASPEN Parenteral Nutrition Safety Consen-
sus Recommendations6 noted that adult patients usually
tolerate abrupt discontinuation of PN without significant
risk of hypoglycemia but that many patients receiving
home PN are frequently ordered a 30-minute to 60-minute
taper-down period because most ambulatory PN infusion
pumps can perform this function automatically. However,
the ASPEN recommendations note that pediatric patients
less than 3 years are more prone to hypoglycemia after
abrupt discontinuation of PN, and so require a taper-
down period prior to PN discontinuation. The recom-
mendations also call for close glucose monitoring at the
beginning, during, and end of infusion when transition-
ing patients from continuous to cyclic PN with decrease
in glucose monitoring once glycemic control has been
established.
The number of steps in the taper varies from 1 step
to multiple steps, and the time period of the taper varies
from 30 minutes to 3 hours. So, all inpatient EHRs should
have the functionality to order, document, and assist the
caregiver in the performance of taper up and/or taper down
of cyclic PNwith a various number of steps in the taper and
various length of time of the taper. EHRs should be able to
accommodate at least the following regimens:
 Automatic infusion pump taper – These pumps will
automatically taper the PN rate up or down during
the time period specified as well as adjust the rate
between taper periods to infuse the entire amount
of PN ordered. Thus, the order needs to have the
availability of a taper up and/or a taper down and
each taper period needs to be able to be ordered in
increments of 30 minutes in a range of 30 minutes to
3 hours.
 Manual taper – needs to have several different taper-
up and/or taper-down regimens available (Table 4)
as well as a custom taper for patients that require
other taper-up and/or taper-down options. Also, the
EHR should calculate the rate that the PN should
run between taper periods to infuse the entire amount
of PN ordered. The rates of infusions during the
different steps in the taper up and taper down should
be called out on theMAR, and the EHR should have
reminders in place for the nursing staff regarding
when and how the rates need to be changed.
Transition of PN From Hospital to
Home/Alternative Care Setting and Vice Versa
Approximately 40,000 individuals in the U.S. are dependent
on home PN to sustain and improve their quality of
life.70,71 Hospitalized patients receiving PN are sometimes
dischargedwith continuation of PN in the home or alternate
care setting (home PN), and patients receiving home PN
are frequently hospitalized, requiring continuation of the
PN during hospitalization. These scenarios require trans-
ferring the PN orders back and forth between the hospital
pharmacy (or outsourced pharmacy used by the hospital)
and the pharmacy preparing the PN for the patient in the
home/alternative care setting. This transition of PN orders
has been challenging with many EHRs due to inability to
electronically transfer orders between systems, resulting in
ordering home PN on paper outside of the EHR or entering
homePNorders into the hospital EHR froma homePNbag
label or paper-faxed order from the home PN pharmacy.
Both of these scenarios require manual transcription of
the PN order and may involve transitioning between 2
PN order strategies with different component concentra-
tions, dose units, etc., which increases the risk of misin-
terpretation of dosing, miscalculations, and transcription
errors.
As HIT systems evolve, transmitting a PN order to
the receiving entity (hospital pharmacy to home/alternative
care setting pharmacy or vice versa) electronically without
the need for manual transcription is essential for patient
safety and to decrease potential errors. Integrating PN
recommendations into evolving HIT standards will be
critical to supporting consistent, standardized PN orders,
including providing complete PN orders as patients move
across healthcare settings. In the U.S., transitions of care
guidelines are driven by requirements of interoperability72
via the Office of the National Coordinator (ONC) for HIT
Certification Program73 and the Improving Medicare Post-
Acute Care Transformation (IMPACT) Act of 2014.74 The
IMPACTAct points to theHL7Consolidated Clinical Doc-
ument Architecture R2.1 HIT standard for electronic tran-
sitions of care guidance. While there are multiple standards
which allow for including PN orders across care settings, it
is critical for PN orders to be included in HIT standards
guidance via the latest version of the ONC Interoperability
Standards Certification (at publication, the 2015 Edition
Health IT Certification Criteria)75 and also to evolving HIT
standards via the ONC Interoperability Standards Advi-
sory (at publication, 2017 Final Interoperability Standards
Advisory).76
EHR systems must have the functionality to allow the
provider to quickly and easily review the last PN orders
within the EHR from the hospital, enter any modifications
to the PN orders needed for home PN, and send these
home PN orders to the home infusion company in a clear,
concise, and standardized fashion that is compatible with
the recommended PN ordering and labeling standards and
guidelines. Similar functionality should be available when
ordering a PN admixture during hospitalization based on a
previous home PN order.
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Table 4. Different Manual Taper-Up and Taper-Down Regimens That Should Be Available Within the EHR.a
Taper Up Taper Down
Taper Regimens Time period Rate adjustment Time period Rate adjustment
1 hour/1 step  Start Infusion
 1 hour after start
infusion
 1/2 full rate
 Full rate + differ-
ence to make up
for taper
 1 hour prior to end
of infusion
 End of infusion
 1/2 full rate
 Stop infusion
1 hour/2 step  Start Infusion
 30 minutes after
start infusion
 1 hour after start
 1/3 full rate
 2/3 full rate
 Full rate + differ-
ence to make up
for taper
 1 hour prior to end
of infusion
 30 minutes prior
to end of infusion
 End of infusion
 2/3 full rate
 1/3 full rate
 Stop infusion
2 hour/2 step  Start Infusion
 1 hour after start
infusion
 2 hours after start
 1/3 full rate
 2/3 full rate
 Full rate + differ-
ence to make up
for taper
 2 hours prior to
end of infusion
 1 hour prior to end
of infusion
 End of infusion
 2/3 full rate
 1/3 full rate
 Stop infusion
aThese recommendations are not intended to supersede the judgment of the healthcare professional based on the circumstances of the individual
patient. EHR, electronic health record.
Summary
Ordering and managing PN therapy using EHRs is a
complex and multistep process that involves multiple clin-
icians from multiple, different specialties. This consensus
statement serves to identify the best practices to date for
electronic ordering of PN using HIT. As HIT standards
become more prevalent in the infrastructure of health
systems, these best practices need to be integrated into
evolving and mature HIT standards, and the incorpora-
tion of these standards into work practices, policy, and
design/build of EHR technology should result in safer
processes for ordering, administering, and managing PN
therapy. EHRs should include the following PN therapy
functionalities:
1. Use standardized and validated PN order and la-
beling templates as recommended by ASPEN (see
Figures 1–7).
2. Design PN orders to facilitate ordering based on
ASPEN recommendations and incorporate CDS to
guide the prescriber on requirements and maxi-
mal limits for macronutrients and micronutrient for
adult, pediatric, and neonatal patients.
3. Analyze workflow from patient-specific PN ordering
to administration to the patient and documentation
of delivered PN admixtures in such a way as to
minimize manual human transcription or double
documentation and provide appropriate CDS sup-
port in all of these steps.
4. Include the functionality to order cyclic PNwith and
without taper up and/or taper down.
5. Include the functionality to transition from hospital
PN orders to home PN orders and vice versa.
Many of the current EHRs do not incorporate 1 or
more of the above in their build and/or workflow. EHR
vendors need to recognize these deficiencies and actively
pursue the clinical nutrition expertise to enhance and
optimize these areas. Nutrition-support clinicians need to
engage EHR vendors, the healthcare system EHR build
team, and the medical and administrative leadership within
their healthcare system to be involved in the process of pur-
chasing, building, training, implementing, and optimizing
their EHR to promote inclusion of the above functionalities
within the PN therapy workflow. These steps will result
in significant improvement in safety for patients receiving
PN therapy. Optimization of the EHR and CDS does not
replace the requirement that the clinicians and caregivers
involved in the PN workflow must be adequately educated,
trained, and experienced in PN therapy.
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